KR102104384B1 - 개선된 상승작용성 항-당뇨병성 조성물 - Google Patents

개선된 상승작용성 항-당뇨병성 조성물 Download PDF

Info

Publication number
KR102104384B1
KR102104384B1 KR1020147017070A KR20147017070A KR102104384B1 KR 102104384 B1 KR102104384 B1 KR 102104384B1 KR 1020147017070 A KR1020147017070 A KR 1020147017070A KR 20147017070 A KR20147017070 A KR 20147017070A KR 102104384 B1 KR102104384 B1 KR 102104384B1
Authority
KR
South Korea
Prior art keywords
inulin
composition
sulfonylurea
sulfonamide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147017070A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002575A (ko
Inventor
닉 나세르 고르가니
Original Assignee
오즈스타 테라피우틱스 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904887A external-priority patent/AU2011904887A0/en
Application filed by 오즈스타 테라피우틱스 피티와이 엘티디 filed Critical 오즈스타 테라피우틱스 피티와이 엘티디
Publication of KR20150002575A publication Critical patent/KR20150002575A/ko
Application granted granted Critical
Publication of KR102104384B1 publication Critical patent/KR102104384B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020147017070A 2011-11-23 2012-11-23 개선된 상승작용성 항-당뇨병성 조성물 Active KR102104384B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2011904887A AU2011904887A0 (en) 2011-11-23 Improved synergistic anti-diabetic compositions
AU2011904887 2011-11-23
AU2012902723A AU2012902723A0 (en) 2012-06-27 Improved synergistic anti-diabetic compositions -II
AU2012902723 2012-06-27
PCT/AU2012/001442 WO2013075172A1 (en) 2011-11-23 2012-11-23 Improved synergistic anti-diabetic compositions

Publications (2)

Publication Number Publication Date
KR20150002575A KR20150002575A (ko) 2015-01-07
KR102104384B1 true KR102104384B1 (ko) 2020-04-27

Family

ID=48468910

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147017070A Active KR102104384B1 (ko) 2011-11-23 2012-11-23 개선된 상승작용성 항-당뇨병성 조성물

Country Status (11)

Country Link
US (1) US9737559B2 (cg-RX-API-DMAC10.html)
EP (1) EP2782586A4 (cg-RX-API-DMAC10.html)
JP (2) JP2014533702A (cg-RX-API-DMAC10.html)
KR (1) KR102104384B1 (cg-RX-API-DMAC10.html)
CN (1) CN104244958B (cg-RX-API-DMAC10.html)
AU (1) AU2012343332B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014012401A2 (cg-RX-API-DMAC10.html)
CA (1) CA2861661C (cg-RX-API-DMAC10.html)
IN (1) IN2014KN01304A (cg-RX-API-DMAC10.html)
RU (1) RU2642633C2 (cg-RX-API-DMAC10.html)
WO (1) WO2013075172A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (zh) * 2019-01-15 2020-09-01 张惊宇 一种治疗糖尿病周围神经痛的药物及其用途
RU2741079C1 (ru) * 2020-04-06 2021-01-22 Общество С Ограниченной Ответственностью "Технологии Дкв" Пищевая добавка «пребио дкв»

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861173A (zh) 2005-05-13 2006-11-15 王锦 糖尿病人营养治疗药品膳食纤维素粉产品
JP2008500955A (ja) * 2003-10-27 2008-01-17 イノディア インコーポレイテッド 糖尿病の治療に使用するための方法及び組成物
US20090214511A1 (en) * 2008-02-21 2009-08-27 Trung Hong Tran Digestible compositions of inulin for managing blood glucose levels

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082842A (en) * 1975-02-21 1978-04-04 Armando Nahle Medicant composition for the treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2206821T3 (es) * 1997-06-23 2004-05-16 Societe Des Produits Nestle S.A. Uso de una composicion nutritiva para la preparacion de una composicion liquida para diabeticos.
US20030130205A1 (en) 2000-04-12 2003-07-10 Christian Samuel T. Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
WO2004070009A2 (en) * 2003-01-31 2004-08-19 Targesome Inc. Targeted multivalent macromolecules
JP2006052191A (ja) * 2004-08-16 2006-02-23 Taiyo Kagaku Co Ltd 糖尿病予防、改善、または治療用組成物
EP1893041A4 (en) 2005-06-17 2009-05-13 Henry H Ottens Mfg Company Inc FIBER-REINFORCED CEREALS, CEREAL BARS AND FOODS AND METHODS OF MAKING
EP1832179B1 (en) * 2005-12-20 2018-11-07 N.V. Nutricia Carbohydrate composition and flat glucose response
US20100303931A1 (en) * 2007-05-10 2010-12-02 L'oreal Cosmetic composition comprising an inulin derivative in the form of an emulsion expanded in volume
GB0907019D0 (en) * 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
DK2419114T4 (da) * 2009-05-01 2019-05-27 Uas Laboratories Llc Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
CA2806619C (en) * 2010-05-24 2018-05-22 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500955A (ja) * 2003-10-27 2008-01-17 イノディア インコーポレイテッド 糖尿病の治療に使用するための方法及び組成物
CN1861173A (zh) 2005-05-13 2006-11-15 王锦 糖尿病人营养治疗药品膳食纤维素粉产品
US20090214511A1 (en) * 2008-02-21 2009-08-27 Trung Hong Tran Digestible compositions of inulin for managing blood glucose levels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Endocrinology. 2005. Vol.185, pp.457-465.*

Also Published As

Publication number Publication date
JP6609287B2 (ja) 2019-11-20
IN2014KN01304A (en) 2015-10-16
EP2782586A1 (en) 2014-10-01
JP2017226672A (ja) 2017-12-28
KR20150002575A (ko) 2015-01-07
RU2014125249A (ru) 2015-12-27
JP2014533702A (ja) 2014-12-15
WO2013075172A1 (en) 2013-05-30
CA2861661C (en) 2021-03-16
RU2642633C2 (ru) 2018-01-25
US20140303118A1 (en) 2014-10-09
AU2012343332A1 (en) 2014-07-17
BR112014012401A2 (pt) 2017-06-13
AU2012343332B2 (en) 2017-03-16
CN104244958A (zh) 2014-12-24
EP2782586A4 (en) 2015-07-01
CN104244958B (zh) 2017-11-17
CA2861661A1 (en) 2013-05-30
US9737559B2 (en) 2017-08-22

Similar Documents

Publication Publication Date Title
KR101694136B1 (ko) Ｓｇｌｔ２ 억제제, ｄｐｐ－ｉｖ 억제제 및 임의로 추가의 당뇨병 치료제를 포함하는 약제학적 조성물 및 이의 용도
EP2552442A1 (en) Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
JP2005213227A (ja) Ｄ−プシコースの血糖上昇抑制効果の利用
US20090214511A1 (en) Digestible compositions of inulin for managing blood glucose levels
EP1863472A2 (en) Amino acid composition for improving glucose tolerance
EP1328280B1 (en) Composition for the treatment of dysglucaemia and method for the production of said composition
US20200352968A1 (en) Methods for reducing the weight loss or increasing the weight of a feline in need thereof
JP6609287B2 (ja) 改良された相乗作用を示す抗糖尿病、抗高血糖症又は抗副作用のための医薬組成物及び製剤
WO2008054193A1 (en) Nutritional products that comprise saccharide oligomers
Berger To bridge science and patient care in diabetes
EP2352505B1 (en) D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
JP5897796B2 (ja) 血糖低下剤及びそれを添加してなる糖尿病の予防又は症状改善のための飲食品
Herz et al. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus
Charney et al. Management of blood glucose and diabetes in the critically ill patient receiving enteral feeding
CN104127816B (zh) 一种治疗糖尿病的药物组合物及其制备方法和用途
TWI459958B (zh) 調節血糖中草藥組成物及其製備方法
TWI912740B (zh) 苦瓜外泌體與苦瓜胰島素受體-結合蛋白質的組合在降血糖上的用途
Reza et al. Pharmacokinetic Comparison and Bioequivalence Evaluation of Two Empagliflozin/Metformin Fixed-Dose Combination Tablets in Healthy Subjects under Fed Conditions
KR20130125745A (ko) 에스쿨린을 포함하는 조성물
TW202615019A (zh) Glp-1r激動劑與恩格列淨的藥物組合物及用途
Young et al. Pharmacologic Management of Type 2 Diabetes Mellitus: Part 2
KR100500158B1 (ko) 레반을 이용한 비만 개선 식이 조성물
JP2023026265A (ja) 肥満，高血糖モデルの作製方法及び予防及び治療の評価方法
LeRoith et al. Loss of glucose homoeostasis: implications of basal glycaemia in type 2 diabetes*.
CN114794487A (zh) 一种治疗糖尿病的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6